keyword
MENU ▼
Read by QxMD icon Read
search

Joaquim bellmunt

keyword
https://www.readbyqxmd.com/read/29277584/comparative-effectiveness-of-robot-assisted-vs-open-radical-cystectomy
#1
Nawar Hanna, Jeffrey J Leow, Maxine Sun, David F Friedlander, Thomas Seisen, Firas Abdollah, Stuart R Lipsitz, Mani Menon, Adam S Kibel, Joaquim Bellmunt, Toni K Choueiri, Quoc-Dien Trinh
OBJECTIVES: Over the past decade, robot-assisted radical cystectomy (RARC) has gained traction as an alternative to the conventional open approach open radical cystectomy (ORC). However, the benefits of RARC over ORC remain unclear. Our objective was to conduct a comparative effectiveness analysis between RARC and ORC using data from the National Cancer Data Base. MATERIALS AND METHODS: Within the National Cancer Data Base, we identified patients with localized muscle-invasive bladder cancer who underwent RC between 2010 and 2013...
December 22, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/29259186/mutational-patterns-in-chemotherapy-resistant-muscle-invasive-bladder-cancer
#2
David Liu, Philip Abbosh, Daniel Keliher, Brendan Reardon, Diana Miao, Kent Mouw, Amaro Weiner-Taylor, Stephanie Wankowicz, Garam Han, Min Yuen Teo, Catharine Cipolla, Jaegil Kim, Gopa Iyer, Hikmat Al-Ahmadie, Essel Dulaimi, David Y T Chen, R Katherine Alpaugh, Jean Hoffman-Censits, Levi A Garraway, Gad Getz, Scott L Carter, Joaquim Bellmunt, Elizabeth R Plimack, Jonathan E Rosenberg, Eliezer M Van Allen
Despite continued widespread use, the genomic effects of cisplatin-based chemotherapy and implications for subsequent treatment are incompletely characterized. Here, we analyze whole exome sequencing of matched pre- and post-neoadjuvant cisplatin-based chemotherapy primary bladder tumor samples from 30 muscle-invasive bladder cancer patients. We observe no overall increase in tumor mutational burden post-chemotherapy, though a significant proportion of subclonal mutations are unique to the matched pre- or post-treatment tumor, suggesting chemotherapy-induced and/or spatial heterogeneity...
December 19, 2017: Nature Communications
https://www.readbyqxmd.com/read/29219016/pembrolizumab-in-the-treatment-of-advanced-urothelial-cancer
#3
Kevin T Lundgren, Matthew S Farina, Joaquim Bellmunt
Pembrolizumab is a humanized monoclonal antibody that targets PD-1. In the Phase III trial KEYNOTE-045, pembrolizumab was associated with a significant overall survival benefit when compared with docetaxel, paclitaxel and vinflunine in second line metastatic urothelial carcinoma (UC). Additionally, in the first line, early results from an interim analysis of the Phase II trial Keynote-052 study indicated that pembrolizumab is efficacious for cisplatin-ineligible patients. Based on data from these trials, pembrolizumab was the most recent among the five checkpoint inhibitors tested in UC to be approved by the US FDA in May 2017...
December 2017: Future Oncology
https://www.readbyqxmd.com/read/29203837/urothelial-cancer-in-2017-changes-in-expectations-for-metastatic-urothelial-carcinoma
#4
Joaquim Bellmunt, Rosa Nadal
No abstract text is available yet for this article.
December 5, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/29198325/ercc1-as-a-prognostic-factor-for-survival-in-patients-with-advanced-urothelial-cancer-treated-with-platinum-based-chemotherapy-a-systematic-review-and-meta-analysis
#5
REVIEW
Yuksel Urun, Jeffrey J Leow, Andre P Fay, Laurence Albiges, Toni K Choueiri, Joaquim Bellmunt
BACKGROUND: The predictive role of excision repair cross-complementing group 1 (ERCC1) as a predictive factor in patients with advanced urothelial cancer (AUC) treated with platinum-based treatment is not well defined. Here, we evaluate the role of ERCC1 in patients with AUC treated with platinum-based treatment. METHODS: We performed comprehensive, systematic computerized search to identify relevant studies through Medline, Embase, Cochrane Controlled Trials Register (CCTR) databases and abstracts from American Society of Clinical Oncology (ASCO) and ASCO Genitourinary Cancers Symposium, European Society For Medical Oncology (ESMO) and European Association of Urology (EAU) meeting up to July 2015...
December 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/29158104/impact-of-primary-tumor-location-on-survival-from-eortc-advanced-urothelial-cancer-studies
#6
Marco Moschini, Shahrokh F Shariat, Morgan Rouprêt, Maria De Santis, Joaquim Bellmunt, Cora N Sternberg, Bertrand Tombal, Laurence Collette
OBJECTIVE: The prognostic relevance of primary location of urothelial carcinoma (UC) on survival has been poorly investigated. METHODS: The prospectively collected data from three EORTC advanced UC studies 30924 (M-VAC versus high dose M-VAC), 30986 (MCAVI versus GC arm, among patients unfit for CDDP) and 30987 (GC-Paclitaxel versus GC, among patients fit for CDDP) were used. Patients were grouped by primary tumor location as bladder (BCa) versus upper tract urothelial carcinoma (UTUC)...
November 17, 2017: Journal of Urology
https://www.readbyqxmd.com/read/29158079/bone-metastases-as-the-only-metastatic-site-in-patients-with-urothelial-carcinoma-focus-on-a-special-patient-population
#7
Andrea Necchi, Gregory R Pond, Sumanta K Pal, Neeraj Agarwal, Daniel W Bowles, Elizabeth R Plimack, Evan Y Yu, Sylvain Ladoire, Jack Baniel, Simon Crabb, Gunter Niegisch, Sandy Srinivas, Dominik R Berthold, Jonathan E Rosenberg, Thomas Powles, Aristotelis Bamias, Lauren C Harshman, Joaquim Bellmunt, Matthew D Galsky
BACKGROUND: Patients with exclusive bone metastatic spread from urothelial carcinoma (UC) throughout their disease course represent a rare subgroup with unique clinical features. These patients deserved special consideration in a retrospective multicenter study. PATIENTS AND METHODS: Analyses were made from a pool of 1911 patients with a diagnosis of metastatic UC, from 23 centers. Baseline characteristics, access to treatment, and outcomes were analyzed according to metastatic spread...
November 1, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29137449/differential-side-effects-profile-in-patients-with-mcrpc-treated-with-abiraterone-or-enzalutamide-a-meta-analysis-of-randomized-controlled-trials
#8
REVIEW
Raphael B Moreira, Marcio Debiasi, Edoardo Francini, Pier V Nuzzo, Guillermo De Velasco, Fernando C Maluf, Andre P Fay, Joaquim Bellmunt, Toni K Choueiri, Fabio A Schutz
Background: Abiraterone and enzalutamide are currently approved for mCRPC patients. Both drugs have distinct mechanisms of action and may have different toxicity profile. There are limited data comparing the side effects of abiraterone and enzalutamide. We performed a meta-analysis of randomized controlled trials (RCT) to better characterize the risk of adverse events associated with both drugs. Methods: We performed a literature search on MEDLINE for studies reporting abiraterone and enzalutamide side effects from January 1966 to July 31, 2015...
October 13, 2017: Oncotarget
https://www.readbyqxmd.com/read/29121502/the-prognostic-role-of-epigenetic-dysregulation-in-bladder-cancer-a-systematic-review
#9
REVIEW
David Casadevall, Anaïs Yacine Kilian, Joaquim Bellmunt
BACKGROUND: Despite adequate treatment and follow-up, around one fifth of patients with localized bladder cancer will present with disease progression. Adequate prognostic biomarkers are lacking to define patients who are at risk. Mutations in chromatin remodeling genes are more frequently found in bladder cancer than in any other solid tumor. However, the prognostic relevance of epigenetic dysregulation has not been established and may offer an opportunity for biomarker discovery. METHODS: Looking for prognostic epigenetic factors, we performed a comprehensive PubMed search using keywords such as "bladder cancer", "chromatin remodeling", "gene methylation" and "epigenetics"...
November 6, 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/28988769/comprehensive-molecular-characterization-of-muscle-invasive-bladder-cancer
#10
A Gordon Robertson, Jaegil Kim, Hikmat Al-Ahmadie, Joaquim Bellmunt, Guangwu Guo, Andrew D Cherniack, Toshinori Hinoue, Peter W Laird, Katherine A Hoadley, Rehan Akbani, Mauro A A Castro, Ewan A Gibb, Rupa S Kanchi, Dmitry A Gordenin, Sachet A Shukla, Francisco Sanchez-Vega, Donna E Hansel, Bogdan A Czerniak, Victor E Reuter, Xiaoping Su, Benilton de Sa Carvalho, Vinicius S Chagas, Karen L Mungall, Sara Sadeghi, Chandra Sekhar Pedamallu, Yiling Lu, Leszek J Klimczak, Jiexin Zhang, Caleb Choo, Akinyemi I Ojesina, Susan Bullman, Kristen M Leraas, Tara M Lichtenberg, Catherine J Wu, Nicholaus Schultz, Gad Getz, Matthew Meyerson, Gordon B Mills, David J McConkey, John N Weinstein, David J Kwiatkowski, Seth P Lerner
We report a comprehensive analysis of 412 muscle-invasive bladder cancers characterized by multiple TCGA analytical platforms. Fifty-eight genes were significantly mutated, and the overall mutational load was associated with APOBEC-signature mutagenesis. Clustering by mutation signature identified a high-mutation subset with 75% 5-year survival. mRNA expression clustering refined prior clustering analyses and identified a poor-survival "neuronal" subtype in which the majority of tumors lacked small cell or neuroendocrine histology...
October 19, 2017: Cell
https://www.readbyqxmd.com/read/28967485/first-line-pembrolizumab-in-cisplatin-ineligible-patients-with-locally-advanced-and-unresectable-or-metastatic-urothelial-cancer-keynote-052-a-multicentre-single-arm-phase-2-study
#11
Arjun V Balar, Daniel Castellano, Peter H O'Donnell, Petros Grivas, Jacqueline Vuky, Thomas Powles, Elizabeth R Plimack, Noah M Hahn, Ronald de Wit, Lei Pang, Mary J Savage, Rodolfo F Perini, Stephen M Keefe, Dean Bajorin, Joaquim Bellmunt
BACKGROUND: More than half of all patients with advanced urothelial cancer cannot receive standard, first-line cisplatin-based chemotherapy because of renal dysfunction, poor performance status, or other comorbidities. We assessed the activity and safety of first-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer. METHODS: In this multicentre, single-arm, phase 2 study (KEYNOTE-052), cisplatin-ineligible patients with advanced urothelial cancer who had not been previously treated with systemic chemotherapy were recruited from 91 academic medical centres in 20 countries...
September 26, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28962591/erratum-to-society-for-immunotherapy-of-cancer-consensus-statement-on-immunotherapy-for-the-treatment-of-bladder-carcinoma
#12
Ashish M Kamat, Joaquim Bellmunt, Matthew D Galsky, Badrinath R Konety, Donald L Lamm, David Langham, Cheryl T Lee, Matthew I Milowsky, Michael A O'Donnell, Peter H O'Donnell, Daniel P Petrylak, Padmanee Sharma, Eila C Skinner, Guru Sonpavde, John A Taylor, Prasanth Abraham, Jonathan E Rosenberg
No abstract text is available yet for this article.
September 28, 2017: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/28923700/venous-thromboembolism-risk-in-patients-with-locoregional-urothelial-tract-tumors
#13
Jorge D Ramos, Jonathan T Wingate, Roman Gulati, Elizabeth R Plimack, Lauren C Harshman, Thomas Powles, Simon J Crabb, Guenter Niegisch, Joaquim Bellmunt, Sylvain Ladoire, Ugo De Giorgi, Syed Hussain, Ajjai S Alva, Jack Baniel, Neeraj Agarwal, Jonathan E Rosenberg, Ulka N Vaishampayan, Matthew D Galsky, Evan Y Yu
BACKGROUND: Venous thromboembolism (VTE) is common in cancer patients, but there is limited data on patients with urothelial tract tumors (UTT). We previously identified several associative factors for increased VTE rates in patients with metastatic UTT. In this study, we assessed the frequency, associative factors, and impact on survival of VTE in patients with locoregional UTT. METHODS: Patients with locoregional bladder, upper urinary tract, or urethral cancer were included in this multi-center study from 29 academic institutions...
August 24, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28922341/-working-toward-understanding-oligo-and-polymetastatic-prostate-cancer
#14
Brian F Chapin, Joaquim Bellmunt
No abstract text is available yet for this article.
November 2017: Current Opinion in Urology
https://www.readbyqxmd.com/read/28916369/antiangiogenesis-to-curb-urothelial-cancer
#15
Joaquim Bellmunt
No abstract text is available yet for this article.
September 12, 2017: Lancet
https://www.readbyqxmd.com/read/28899722/effect-of-nonurothelial-histologic-variants-on-the-outcomes-of-radical-cystectomy-for-nonmetastatic-muscle-invasive-urinary-bladder-cancer
#16
Malte W Vetterlein, Thomas Seisen, Jeffrey J Leow, Mark A Preston, Maxine Sun, David F Friedlander, Christian P Meyer, Felix K-H Chun, Stuart R Lipsitz, Mani Menon, Adam S Kibel, Joaquim Bellmunt, Toni K Choueiri, Quoc-Dien Trinh
INTRODUCTION: Knowledge of the comparative oncologic outcomes of histologic variants after radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC) relies on small case series. We compared the effect of pure squamous cell carcinoma, adenocarcinoma, and neuroendocrine carcinoma compared with pure urothelial carcinoma (PUC) on overall survival (OS) and pathologic tumor, lymph node, and surgical margin status after RC. PATIENTS AND METHODS: Using the National Cancer Database, we retrospectively examined patients undergoing RC for MIBC from 2003 to 2011...
August 24, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28864222/upper-tract-urothelial-carcinomas-prognostic-factors-and-outcomes-in-patients-with-non-lymph-node-distant-metastasis
#17
Elena Sevillano, Lillian Werner, Dominick Bossé, Aly-Khan A Lalani, Stephanie A M Wankowicz, Guillermo de Velasco, Matthew Farina, Kevin Lundgren, Toni K Choueiri, Aranzazu González Del Alba, Joaquim Bellmunt
BACKGROUND: Upper tract urothelial carcinomas (UTUCs) are increasingly recognized as separate malignancies. Additional insight into clinical outcomes and key prognostic factors are needed. OBJECTIVES: To detail outcomes of patients with UTUCs recurring after radical nephroureterectomy (RNU) and to determine a risk score that predicts outcomes of patients with non-lymph node distant metastasis. DESIGN, SETTING, AND PARTICIPANTS: Chart review of all patients who had an extraurothelial recurrence after RNU for UTUC at Dana-Farber Cancer Institute between 2009 and 2014...
August 2, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28853615/radical-cystectomy-or-bladder-preservation-with-radiochemotherapy-in-elderly-patients-with-muscle-invasive-bladder-cancer-retrospective-international-study-of-cancers-of-the-urothelial-tract-risc-investigators
#18
Jihane Boustani, Aurélie Bertaut, Matthew D Galsky, Jonathan E Rosenberg, Joaquim Bellmunt, Thomas Powles, Federica Recine, Lauren C Harshman, Simon Chowdhury, Guenter Niegisch, Evan Y Yu, Sumanta K Pal, Ugo De Giorgi, Simon J Crabb, Matthieu Caubet, Loïc Balssa, Matthew I Milowsky, Sylvain Ladoire, Gilles Créhange
BACKGROUND: Radical cystectomy (RC) and radiochemotherapy (RCT) are curative options for muscle-invasive bladder cancer (MIBC). Optimal treatment strategy remains unclear in elderly patients. MATERIAL AND METHODS: Patients aged 80 years old and above with T2-T4aN0-2M0-Mx MIBC were identified in the Retrospective International Study of Cancers of the Urothelial Tract (RISC) database. Patients treated with RC were compared with those treated with RCT. The impact of surgery on overall survival (OS) was assessed using a Cox proportional hazard model...
August 30, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/28837718/adjuvant-chemotherapy-vs-observation-for-patients-with-adverse-pathologic-features-at-radical-cystectomy-previously-treated-with-neoadjuvant-chemotherapy
#19
Thomas Seisen, Asha Jamzadeh, Jeffrey J Leow, Morgan Rouprêt, Alexander P Cole, Stuart R Lipsitz, Adam S Kibel, Paul L Nguyen, Maxine Sun, Mani Menon, Joaquim Bellmunt, Toni K Choueiri, Quoc-Dien Trinh
Importance: Despite existing evidence of a benefit associated with cisplatin-based adjuvant chemotherapy (AC) after radical cystectomy (RC) for chemotherapy-naive patients with pT3/T4 and/or pN+ urothelial carcinoma of the bladder (UCB), to our knowledge, no studies have addressed the effectiveness of AC in those who received neoadjuvant chemotherapy (NAC) before surgery. Objective: To assess the comparative effectiveness of AC vs observation for patients with pT3/T4 and/or pN+ UCB previously treated with NAC and RC...
August 24, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28815048/society-for-immunotherapy-of-cancer-consensus-statement-on-immunotherapy-for-the-treatment-of-bladder-carcinoma
#20
Ashish M Kamat, Joaquim Bellmunt, Matthew D Galsky, Badrinath R Konety, Donald L Lamm, David Langham, Cheryl T Lee, Matthew I Milowsky, Michael A O'Donnell, Peter H O'Donnell, Daniel P Petrylak, Padmanee Sharma, Eila C Skinner, Guru Sonpavde, John A Taylor, Prasanth Abraham, Jonathan E Rosenberg
The standard of care for most patients with non-muscle-invasive bladder cancer (NMIBC) is immunotherapy with intravesical Bacillus Calmette-Guérin (BCG), which activates the immune system to recognize and destroy malignant cells and has demonstrated durable clinical benefit. Urologic best-practice guidelines and consensus reports have been developed and strengthened based on data on the timing, dose, and duration of therapy from randomized clinical trials, as well as by critical evaluation of criteria for progression...
2017: Journal for Immunotherapy of Cancer
keyword
keyword
22154
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"